EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8

Francesco Fiorentino iD, Sara Sementilli, Martina Menna, Federica Turrisi, Stefano Tomassi iD, Francesca Romana Pellegrini, Angela Iuzzolino, Francesca D'Acunzo, Alessandra Feoli iD, Hannah Wapenaar, Sophie Taraglio, Caterina Fraschetti iD und 7 weitere

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Francesco Fiorentino und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, Rome 00185, Italy. Hauptthemen laut MEDLINE: Lysine Acetyltransferases, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regione Lazio, Sapienza Universit? di Roma, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KAT8 is a lysine acetyltransferase primarily catalyzing the acetylation of Lys16 of histone H4 (H4K16). KAT8 dysregulation is linked to the development and metastatization of many cancer types, including non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML). Few KAT8 inhibitors have been reported so far, none of which displaying selective activity. Based on the KAT3B/KDAC inhibitor C646, we developed a series of N-phenyl-5-pyrazolone derivatives and identified compounds 19 and 34 as low-micromolar KAT8 inhibitors selective over a panel of KATs and KDACs. Western blot, immunofluorescence, and CETSA experiments demonstrated that both inhibitors selectively target KAT8 in cells. Moreover, 19 and 34 exhibited mid-micromolar antiproliferative activity in different cancer cell lines, including NSCLC and AML, without impacting the viability of nontransformed cells. Overall, these compounds are valuable tools for elucidating KAT8 biology, and their simple structures make them promising candidates for future optimization studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lysine AcetyltransferasesCarcinoma, Non-Small-Cell LungLung NeoplasmsLeukemia, Myeloid, AcuteHumansHistonesAcetylationHistone Acetyltransferases

Substanzen

Lysine AcetyltransferasesHistonesHistone AcetyltransferasesKAT8 protein, human

Autor:innen und Institutionen

  • Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, Rome 00185, Italy.
  • Institute of Molecular Biology and Pathology, National Research Council (CNR), Via degli Apuli 4, Rome 00185, Italy.
  • Department of Pharmacy, University of Naples "Federico II", via Domenico Montesano 49, Naples 80131, Italy.
  • Institute of Biological Systems (ISB), Italian National Research Council (CNR), Sezione Meccanismi di Reazione, c/o Department of Chemistry, Sapienza University of Rome, P. le A. Moro 5, Rome 00185, Italy.
  • Department of Pharmacy, University of Salerno, via Giovanni Paolo II 132, Fisciano (SA) 84084, Italy.
  • Department of Chemical and Pharmaceutical Biology, University of Groningen, Antonius Deusinglaan 1, Groningen 9713 AV, The Netherlands.

ORCID-Profile: Francesco Fiorentino, Stefano Tomassi, Alessandra Feoli, Caterina Fraschetti, Gianluca Sbardella, Frank J Dekker, Antonello Mai, Dante Rotili

Förderung

  • Regione Lazio
  • Sapienza Universit? di Roma
  • Associazione Italiana per la Ricerca sul Cancro
  • Universit? degli Studi di Salerno
  • Banca d'Italia
  • Ministero dell'Universit? e della Ricerca
  • Regione Campania
  • Central European Research Infrastructure Consortium

Zitieren

APA

Fiorentino, F., Sementilli, S., Menna, M., Turrisi, F., Tomassi, S., Pellegrini, F. R., Iuzzolino, A., D'Acunzo, F., Feoli, A., Wapenaar, H., Taraglio, S., Fraschetti, C., Del Bufalo, D., Sbardella, G., Dekker, F. J., Paiardini, A., Trisciuoglio, D., Mai, A., & Rotili, D. (2023). First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01937

Vancouver

Fiorentino F, Sementilli S, Menna M, Turrisi F, Tomassi S, Pellegrini FR, et al. First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01937

BibTeX
@article{Fiorentino2023,
  author = {Fiorentino, Francesco and Sementilli, Sara and Menna, Martina and Turrisi, Federica and Tomassi, Stefano and Pellegrini, Francesca Romana and Iuzzolino, Angela and D'Acunzo, Francesca and Feoli, Alessandra and Wapenaar, Hannah and Taraglio, Sophie and Fraschetti, Caterina and Del Bufalo, Donatella and Sbardella, Gianluca and Dekker, Frank J and Paiardini, Alessandro and Trisciuoglio, Daniela and Mai, Antonello and Rotili, Dante},
  title = {First-in-Class Selective Inhibitors of the Lysine Acetyltransferase KAT8},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01937}
}
Kostenlos starten →